PDI and Empire Genomics to Create Relationship
Complete the form below to unlock access to ALL audio articles.
Population Diagnostics, Inc. has announced that it has agreed to terms with Empire Genomics LLC (EG) to establish an infrastructure for PDI to begin commercializing at full scale its core technology platform.
The core technology of PDI will facilitate the company's primary objective, which is to develop predictive tests for the molecular diagnostic and personalized medicine markets.
The understanding between PDI and EG is multifaceted, where EG intends to purchase access to the core technology platform of PDI to support its internal and collaborative projects, and service/supply relationships with 3rd parties.
PDI intends to use genetic information derived from EG's high quality microarray products and services to build its core technology platform as well as its DNA biomarker discovery program.
PDI and EG also intend to co-market and co-promote the products and services of their respective companies.
"This relationship lends credence to the demand for our normal variation technology platform," commented Jim Chinitz, CEO of Population Diagnostics, "where Empire Genomics intends to incorporate PDI's platform in its services and promote it to its customers."
"Their decision to pursue early access is based primarily on their understanding of our working prototype which has recently elucidated medically relevant biomarkers for Autism."
"In the big picture, when our technology is fully commercialized, it will be utilized internally and shared externally for the discovery of DNA biomarkers in a broad category of simple and complex diseases and also applied to rescuing effective drugs at risk of failing FDA approval."
"Furthermore, I am very pleased to have secured a key source of the highest quality products and services from the Empire Genomics organization led by Dr. Norma Nowak."
"The prescribing medical community is clearly disenchanted with the slow pace of disease biomarker discovery," commented Dr. Eli Hatchwell, Chief Scientific Officer of PDI.
"We believe this to be the result of the current technology and general approach to discovering genetically relevant markers."
"In contrast, our proven methods and internally developed tools will accelerate the discovery process by several orders of magnitude, allowing us to create a 'factory' pipeline which will yield an extensive menu of novel diagnostic tests."
"In essence, we will be able to translate molecular research into benefits at the patient level very rapidly."
